NASDAQ:CNCE

Concert Pharmaceuticals Competitors

$4.41
-0.21 (-4.55 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.32
Now: $4.41
$4.67
50-Day Range
$4.54
MA: $5.66
$6.89
52-Week Range
$4.44
Now: $4.41
$13.50
Volume312,647 shs
Average Volume484,403 shs
Market Capitalization$141.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Competitors

Concert Pharmaceuticals (NASDAQ:CNCE) Vs. MIRM, SIGA, CRNX, ISEE, MGTA, and ALDX

Should you be buying CNCE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Concert Pharmaceuticals, including Mirum Pharmaceuticals (MIRM), SIGA Technologies (SIGA), Crinetics Pharmaceuticals (CRNX), IVERIC bio (ISEE), Magenta Therapeutics (MGTA), and Aldeyra Therapeutics (ALDX).

Concert Pharmaceuticals (NASDAQ:CNCE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Risk and Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Mirum Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concert Pharmaceuticals$1.08 million131.38$-78,170,000.00($3.29)-1.34
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-4.03

Mirum Pharmaceuticals has lower revenue, but higher earnings than Concert Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Concert Pharmaceuticals and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concert Pharmaceuticals-921.38%-55.20%-44.83%
Mirum PharmaceuticalsN/A-61.90%-54.46%

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 72.9% of Mirum Pharmaceuticals shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 45.5% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Concert Pharmaceuticals and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concert Pharmaceuticals00403.00
Mirum Pharmaceuticals00613.14

Concert Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. Mirum Pharmaceuticals has a consensus target price of $40.1667, suggesting a potential upside of 117.82%. Given Concert Pharmaceuticals' higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Summary

Mirum Pharmaceuticals beats Concert Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Concert Pharmaceuticals (NASDAQ:CNCE) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Risk and Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Concert Pharmaceuticals and SIGA Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concert Pharmaceuticals$1.08 million131.38$-78,170,000.00($3.29)-1.34
SIGA Technologies$26.74 million20.84$-7,240,000.00N/AN/A

SIGA Technologies has higher revenue and earnings than Concert Pharmaceuticals.

Profitability

This table compares Concert Pharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concert Pharmaceuticals-921.38%-55.20%-44.83%
SIGA Technologies34.62%37.31%25.33%

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Concert Pharmaceuticals and SIGA Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concert Pharmaceuticals00403.00
SIGA Technologies0000N/A

Concert Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. Given Concert Pharmaceuticals' higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than SIGA Technologies.

Concert Pharmaceuticals (NASDAQ:CNCE) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Crinetics Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concert Pharmaceuticals$1.08 million131.38$-78,170,000.00($3.29)-1.34
Crinetics Pharmaceuticals$1.19 million464.35$-50,420,000.00($2.09)-8.00

Crinetics Pharmaceuticals has higher revenue and earnings than Concert Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Concert Pharmaceuticals and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concert Pharmaceuticals-921.38%-55.20%-44.83%
Crinetics PharmaceuticalsN/A-43.35%-39.73%

Analyst Ratings

This is a summary of current recommendations for Concert Pharmaceuticals and Crinetics Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concert Pharmaceuticals00403.00
Crinetics Pharmaceuticals01302.75

Concert Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. Crinetics Pharmaceuticals has a consensus target price of $35.00, suggesting a potential upside of 109.21%. Given Concert Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats Concert Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Concert Pharmaceuticals (NASDAQ:CNCE) and IVERIC bio (NASDAQ:ISEE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Risk & Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Institutional and Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 84.8% of IVERIC bio shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of IVERIC bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Concert Pharmaceuticals and IVERIC bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concert Pharmaceuticals-921.38%-55.20%-44.83%
IVERIC bioN/A-45.42%-41.94%

Valuation & Earnings

This table compares Concert Pharmaceuticals and IVERIC bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concert Pharmaceuticals$1.08 million131.38$-78,170,000.00($3.29)-1.34
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.28

IVERIC bio has lower revenue, but higher earnings than Concert Pharmaceuticals. IVERIC bio is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Concert Pharmaceuticals and IVERIC bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concert Pharmaceuticals00403.00
IVERIC bio01102.50

Concert Pharmaceuticals presently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. IVERIC bio has a consensus target price of $13.00, suggesting a potential upside of 118.49%. Given Concert Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Concert Pharmaceuticals is more favorable than IVERIC bio.

Summary

IVERIC bio beats Concert Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings & Valuation

This table compares Magenta Therapeutics and Concert Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.31
Concert Pharmaceuticals$1.08 million131.38$-78,170,000.00($3.29)-1.34

Magenta Therapeutics has higher earnings, but lower revenue than Concert Pharmaceuticals. Magenta Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Magenta Therapeutics and Concert Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
Concert Pharmaceuticals-921.38%-55.20%-44.83%

Volatility & Risk

Magenta Therapeutics has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Institutional and Insider Ownership

59.3% of Magenta Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Concert Pharmaceuticals shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by insiders. Comparatively, 10.1% of Concert Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Magenta Therapeutics and Concert Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
Concert Pharmaceuticals00403.00

Magenta Therapeutics currently has a consensus price target of $17.6667, suggesting a potential upside of 60.61%. Concert Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 364.85%. Given Concert Pharmaceuticals' higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Magenta Therapeutics.

Summary

Magenta Therapeutics beats Concert Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Concert Pharmaceuticals (NASDAQ:CNCE) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Aldeyra Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concert Pharmaceuticals$1.08 million131.38$-78,170,000.00($3.29)-1.34
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-5.50

Aldeyra Therapeutics has lower revenue, but higher earnings than Concert Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Concert Pharmaceuticals and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concert Pharmaceuticals-921.38%-55.20%-44.83%
Aldeyra TherapeuticsN/A-73.73%-52.74%

Risk & Volatility

Concert Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Institutional and Insider Ownership

69.7% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Concert Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concert Pharmaceuticals00403.00
Aldeyra Therapeutics011002.91

Concert Pharmaceuticals currently has a consensus price target of $20.50, suggesting a potential upside of 364.85%. Aldeyra Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 130.50%. Given Concert Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Concert Pharmaceuticals is more favorable than Aldeyra Therapeutics.

Summary

Concert Pharmaceuticals beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.


Concert Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.44-0.7%$560.95 millionN/A-5.36
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.26-1.5%$557.19 million$26.74 million18.15
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.73-3.5%$552.58 million$1.19 million-6.97
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.95-3.7%$536.51 millionN/A-4.72
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.00-1.5%$534.12 millionN/A-5.64Analyst Upgrade
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.28-2.6%$532.95 millionN/A-8.74Increase in Short Interest
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.87-1.4%$518.95 millionN/A-8.22Unusual Options Activity
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.11-1.8%$516.12 millionN/A-4.07
Inventiva logo
IVA
Inventiva
0.0$13.34-0.5%$515.32 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$8.11-0.4%$513.97 millionN/A-5.44Analyst Report
Increase in Short Interest
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.96-2.0%$506.22 million$25 million-18.40
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.62-0.8%$503.97 million$59.22 million43.10
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$36.80-0.1%$497.13 million$40,000.00-1.60Upcoming Earnings
XBiotech logo
XBIT
XBiotech
1.0$16.81-2.3%$495.21 millionN/A1.16
89bio logo
ETNB
89bio
1.6$24.77-2.5%$494.06 millionN/A-4.90
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.75-1.7%$493.31 million$58.12 million-15.99Decrease in Short Interest
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.51-1.9%$486.53 million$57.49 million-6.31Increase in Short Interest
AC Immune logo
ACIU
AC Immune
1.3$6.73-4.9%$484.14 million$111.75 million-7.48
Evolus logo
EOLS
Evolus
1.5$10.97-2.7%$479.75 million$34.92 million-5.40Analyst Report
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.19-1.7%$478.45 million$49.65 million-1.68Analyst Upgrade
Akouos logo
AKUS
Akouos
1.6$13.76-12.8%$473.37 millionN/A0.00
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.41-2.8%$469.79 million$72.96 million-3.05Analyst Report
Analyst Revision
Geron logo
GERN
Geron
1.4$1.47-2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.00-3.3%$463.48 millionN/A-2.43
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.44-0.7%$460.98 million$102.31 million6.63Increase in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$460.07 million$17.46 million-1.90
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.47-1.9%$459.79 million$6.07 million-3.57
Altimmune logo
ALT
Altimmune
1.9$12.27-3.7%$455.83 million$5.80 million-6.17Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.96-3.4%$454.37 million$335 million-1.00
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.87-3.7%$453.04 millionN/A-11.98News Coverage
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.36-4.5%$444.43 million$56.50 million0.00Analyst Downgrade
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.60-7.8%$436.43 millionN/A0.00Gap Down
BCEL
Atreca
1.7$11.81-3.6%$434.97 millionN/A-4.19
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.87-1.6%$434.88 million$6.68 million-4.66
MedAvail logo
MDVL
MedAvail
1.9$13.45-0.8%$429.59 million$1.03 million-3.30Increase in Short Interest
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.39-2.4%$426.29 millionN/A-3.44
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$11.50-2.4%$423.40 millionN/A0.00Lockup Expiration
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$34.18-1.7%$422.64 million$206.55 million-17.18
XOMA logo
XOMA
XOMA
1.3$37.50-0.9%$422.18 million$18.37 million-33.78Increase in Short Interest
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.26-0.4%$411.77 million$380,000.000.00Analyst Upgrade
News Coverage
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.07-1.4%$405.40 million$272.30 million-7.04
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
0.9$20.23-0.4%$400.47 million$362.21 million24.37
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$8.17-2.7%$392.29 million$3.89 million-4.28Gap Down
Cue Biopharma logo
CUE
Cue Biopharma
1.3$12.84-0.9%$391.07 million$3.46 million-8.18News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.12-7.8%$391.02 million$36.63 million-4.85Gap Up
Sesen Bio logo
SESN
Sesen Bio
1.2$2.30-0.9%$389.59 millionN/A-5.23Decrease in Short Interest
DURECT logo
DRRX
DURECT
1.4$1.71-4.7%$388.52 million$29.56 million-34.19
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.